A Phase Ia-Ib Dose-escalation Study Evaluating Safety and Efficacy of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) With Concomitant Capecitabine Chemotherapy for Resectable Carcinoma of Exocrine Pancreas.

Trial Profile

A Phase Ia-Ib Dose-escalation Study Evaluating Safety and Efficacy of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) With Concomitant Capecitabine Chemotherapy for Resectable Carcinoma of Exocrine Pancreas.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jan 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
    • 06 Jan 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
    • 19 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top